Avanos Medical FY2026 EPS Forecast Reduced by Zacks Research

Avanos Medical, Inc. (NYSE:AVNS - Free Report) - Equities research analysts at Zacks Research cut their FY2026 earnings estimates for Avanos Medical in a note issued to investors on Tuesday, December 31st. Zacks Research analyst R. Department now anticipates that the company will post earnings of $1.99 per share for the year, down from their prior forecast of $2.00. The consensus estimate for Avanos Medical's current full-year earnings is $1.32 per share.

Separately, StockNews.com lowered shares of Avanos Medical from a "strong-buy" rating to a "buy" rating in a research note on Sunday, November 3rd.

Avanos Medical Stock Down 1.8 %

AVNS stock traded down $0.28 during midday trading on Friday, reaching $15.55. 388,381 shares of the company were exchanged, compared to its average volume of 397,591. The company has a market cap of $714.63 million, a price-to-earnings ratio of 45.74 and a beta of 0.95. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. Avanos Medical has a 1-year low of $15.51 and a 1-year high of $25.36. The stock's 50-day simple moving average is $18.33 and its 200 day simple moving average is $21.04.

Hedge Funds Weigh In On Avanos Medical

Hedge funds have recently modified their holdings of the business. Quarry LP purchased a new position in shares of Avanos Medical during the third quarter worth about $42,000. KBC Group NV lifted its position in Avanos Medical by 63.0% during the 3rd quarter. KBC Group NV now owns 2,833 shares of the company's stock worth $68,000 after acquiring an additional 1,095 shares during the period. Canada Pension Plan Investment Board purchased a new position in shares of Avanos Medical in the 2nd quarter valued at approximately $70,000. XTX Topco Ltd acquired a new position in shares of Avanos Medical in the second quarter valued at approximately $202,000. Finally, Intech Investment Management LLC purchased a new stake in shares of Avanos Medical during the third quarter worth approximately $207,000. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.